leadf
logo-loader
view4D pharma plc

4d pharma's Duncan Peyton outlines crucial next stage for its cancer trial

4d pharma plc's (LON:DDDD) Duncan Peyton updates Proactive's Andrew Scott following the news the next stage of its cancer clinical study is underway with four new sites added in the US to accelerate patient recruitment. Up to 30 people per tumour type will participate in Part B of the company’s phase I/II trial to assess its live biotherapeutic, MRx0518, in combination with immune checkpoint inhibitor Keytruda.

Quick facts: 4D pharma plc

Price: 160 GBX

LSE:DDDD
Market: LSE
Market Cap: £210.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of 4D pharma plc named herein, including the promotion by the Company of 4D pharma plc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Luminex Resources CEO says stay tuned for drill results out of its Condor...

Luminex Resources Corp. (TSXV: LR) (OTCQX: LUMIF) CEO Marshall Koval tells Proactive the Vancouver-based mining company is making progress on its Condor Gold-Copper Project in Zamora-Chinchipe Province, southeast Ecuador. Koval says the group has advanced metallurgy at the site, continuing to...

1 day, 5 hours ago

2 min read